List of Excipients in Branded Drug ITRACONAZOLE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Patriot Pharmaceuticals LLC	ITRACONAZOLE	itraconazole	10147-0150	ADRABETADEX
Patriot Pharmaceuticals LLC	ITRACONAZOLE	itraconazole	10147-0150	CARAMEL
Patriot Pharmaceuticals LLC	ITRACONAZOLE	itraconazole	10147-0150	CHERRY
Patriot Pharmaceuticals LLC	ITRACONAZOLE	itraconazole	10147-0150	HYDROCHLORIC ACID
Patriot Pharmaceuticals LLC	ITRACONAZOLE	itraconazole	10147-0150	PROPYLENE GLYCOL
Patriot Pharmaceuticals LLC	ITRACONAZOLE	itraconazole	10147-0150	SACCHARIN SODIUM

Generic Drugs Containing ITRACONAZOLE

Company	Ingredient	NDC	Excipient
Mylan Pharmaceuticals Inc	itraconazole	0378-5100	FD&C BLUE NO. 2
Mylan Pharmaceuticals Inc	itraconazole	0378-5100	FERRIC OXIDE RED
Mylan Pharmaceuticals Inc	itraconazole	0378-5100	FERRIC OXIDE YELLOW
Mylan Pharmaceuticals Inc	itraconazole	0378-5100	FERROSOFERRIC OXIDE
Mylan Pharmaceuticals Inc	itraconazole	0378-5100	GELATIN
Mylan Pharmaceuticals Inc	itraconazole	0378-5100	HYPROMELLOSE

What are the Most Frequently-Used Excipients in ITRACONAZOLE?

# Of NDCs	Excipient
6	ALCOHOL
10	AMMONIA
1	ASCORBIC ACID
6	BUTYL ALCOHOL
3	CELLULOSE, MICROCRYSTALLINE
3	D&C RED NO. 22

Itraconazole Excipient Strategy and Commercial Opportunities

Last updated: August 21, 2026

Itraconazole is an established triazole antifungal with a persistent formulation problem: very low and pH-dependent aqueous solubility, variable gastrointestinal absorption, food effects, and clinically significant drug-drug interactions. The commercial opportunity is therefore concentrated in delivery systems that improve exposure consistency, reduce administration restrictions, support pediatric or geriatric use, and create differentiated products without relying solely on the active ingredient.

The strongest technical platforms are amorphous solid dispersions, cyclodextrin-based liquids, lipid or self-emulsifying systems, nanocrystals, and multiparticulate capsules. The strongest commercial opportunities are improved oral products, hospital formulations, pediatric liquids, generic substitution, and region-specific products for fungal prophylaxis and chronic mucocutaneous infections.

Why does itraconazole require an excipient-driven formulation strategy?

Itraconazole is a weakly basic, highly lipophilic compound with low water solubility. Its dissolution and absorption vary with gastric acidity, food intake, gastrointestinal motility, and formulation design. The drug is extensively metabolized by CYP3A4 and has transporter-related interaction potential, which limits the degree to which formulation changes can solve all exposure variability.

Key formulation constraints include:

Formulation issue	Commercial consequence
Poor aqueous solubility	Conventional immediate-release tablets have limited bioavailability
pH-dependent dissolution	Reduced gastric acidity can lower absorption
Food sensitivity	Administration instructions differ by dosage form
High pharmacokinetic variability	Therapeutic monitoring is important in several indications
Strong CYP3A4 inhibition and metabolism	Drug interaction risk remains even with improved formulations
Long terminal elimination phase	Accumulation and delayed adverse effects can occur
Taste and dose-volume concerns	Pediatric and liquid products require specialized excipients

The formulation must maintain itraconazole in a dissolved or rapidly dissolving state through the gastrointestinal tract. A formulation that dissolves in the stomach but precipitates after intestinal pH rises may not produce consistent exposure.

What excipients are used in marketed itraconazole products?

Marketed itraconazole products use different excipient strategies rather than a single platform.

Sporanox capsules

Sporanox capsules use itraconazole-coated sugar spheres in a multiparticulate pellet system. The capsule is designed to disperse drug-loaded pellets in the gastrointestinal tract rather than deliver a single compact tablet. The formulation includes hypromellose and polyethylene glycol-based coating components, with capsule shell excipients listed in the prescribing information. The product is administered after a full meal to support absorption (Janssen Pharmaceuticals, 2023).

The commercial value of this architecture is based on:

• High surface area from drug-coated pellets
• Improved dispersion compared with a compressed tablet
• Compatibility with modified-release or enteric coating approaches
• Manufacturing differentiation through pellet layering and coating controls

The limitation is dependence on gastric conditions and food intake. Acid-suppressive therapy can reduce exposure unless administration is managed carefully.

Sporanox oral solution

Sporanox oral solution uses hydroxypropyl-beta-cyclodextrin as a solubilizing excipient. Cyclodextrin forms an inclusion complex with the lipophilic itraconazole molecule, increasing apparent aqueous solubility. The product is supplied at 10 mg/mL and is used under administration conditions that differ from the capsule product (Janssen Pharmaceuticals, 2023).

Cyclodextrin-based liquids offer:

• Higher apparent solubility
• Flexible dose measurement
• Use in patients who cannot swallow capsules
• Potential utility for hospital and pediatric settings

The principal constraints are high excipient load, taste, gastrointestinal tolerability, renal safety considerations for some cyclodextrins, and the need to establish acceptable long-term stability.

Tolsura and SUBA-itraconazole

Tolsura is a 65 mg itraconazole capsule based on Mayne Pharma’s SUBA technology. The platform uses a dispersion approach intended to improve dissolution and exposure relative to conventional itraconazole capsules. The product has different administration instructions from Sporanox capsules and is not dose-equivalent on a milligram-for-milligram basis (U.S. Food and Drug Administration, 2018).

The key excipient strategy is an amorphous dispersion or enhanced-dissolution matrix using polymers such as hypromellose acetate succinate and supporting excipients that promote wetting, dispersion, and physical stability. The formulation is designed to reduce dependence on gastric acidity and food.

The commercial importance of Tolsura is that it creates a branded, differentiated product from an old active ingredient. The value proposition is based on exposure predictability, dosing convenience, and a product-specific clinical and regulatory package rather than new antifungal pharmacology.

What formulation platforms offer the best commercial opportunity for itraconazole?

Amorphous solid dispersions

Amorphous solid dispersions are the highest-value platform for an oral solid product. Polymer selection can include hypromellose acetate succinate, hydroxypropyl methylcellulose, polyvinylpyrrolidone, copovidone, or related precipitation-inhibiting polymers.

A successful itraconazole dispersion must control:

• Drug-polymer miscibility
• Glass-transition behavior
• Moisture uptake
• Amorphous stability
• Supersaturation duration
• Milling and granulation behavior
• Capsule-fill uniformity

The main commercial opportunity is a lower-variability capsule that can compete against both conventional generic capsules and premium branded products. Patentability may arise from composition ranges, process conditions, particle attributes, dissolution profiles, and stability performance.

Cyclodextrin-based oral liquids

Hydroxypropyl-beta-cyclodextrin remains commercially relevant because it enables a liquid dosage form without requiring high concentrations of surfactants or oil phases. Opportunities include:

• Pediatric antifungal treatment
• Patients with dysphagia
• Hospital and oncology use
• Ex-US markets with limited capsule access
• Concentrated liquids with lower administration volume

The main barriers are excipient cost, taste masking, dose-volume limitations, microbial control, packaging compatibility, and renal safety assessment.

Lipid-based and self-emulsifying systems

Self-emulsifying drug delivery systems can improve itraconazole dissolution by presenting the drug in a fine dispersion after contact with gastrointestinal fluids. Candidate components include medium-chain glycerides, long-chain triglycerides, surfactants, and cosolvents.

The commercial advantages are:

• Potentially higher and less variable exposure
• Reduced dependence on gastric dissolution
• Capsule-compatible manufacturing
• Opportunity for softgel or liquid-filled hard-capsule products

The main risks are precipitation after dilution, excipient tolerability, capsule-shell compatibility, oxidation, and complex in vitro-in vivo correlation.

Nanocrystals and nanosuspensions

Itraconazole nanocrystals increase surface area and can accelerate dissolution without requiring a large polymer load. Stabilizers may include surfactants or water-soluble polymers.

Nanocrystal products could support:

• Smaller oral dosage forms
• Fast-dissolving tablets
• Oral suspensions
• Long-acting injectable research programs

The manufacturing burden is higher than for conventional pellets. Particle-size distribution, aggregation, polymorphic conversion, and physical stability require tight control.

Multiparticulate and sprinkle formulations

Multiparticulate systems can improve swallowing and enable dose flexibility. A commercial product could use coated pellets in capsules, sachets, or sprinkle presentations. The principal development issues are:

• Maintaining drug release after opening the capsule
• Avoiding pellet crushing
• Controlling taste and mouthfeel
• Establishing stability in unit-dose packaging
• Demonstrating bioequivalence against the reference product

This platform is particularly relevant to geriatric, pediatric, and long-term prophylaxis markets.

Which itraconazole excipients have the strongest development potential?

Excipient class	Primary function	Opportunity	Main development risk
Hypromellose acetate succinate	Amorphous dispersion and precipitation inhibition	Enhanced capsules and tablets	Physical instability and process sensitivity
Hypromellose	Matrix formation and coating	Pellets, dispersions, modified release	Variable hydration and release behavior
Hydroxypropyl-beta-cyclodextrin	Solubilization	Oral liquids and parenteral products	High dose burden and safety assessment
Copovidone or povidone	Dispersion and binding	Solid dispersions and granulation	Hygroscopicity and recrystallization
Poloxamers	Wetting and solubilization	Suspensions and lipid systems	Oxidative and stability concerns
Sodium lauryl sulfate	Wetting and dissolution enhancement	Solid oral products	Gastrointestinal tolerability
Medium-chain glycerides	Lipid solubilization	Softgels and self-emulsifying systems	Precipitation and capsule compatibility
Silica-based glidants	Flow and process control	High-load capsules and tablets	Powder segregation
Sucralose, flavorants, and ion-exchange resins	Taste masking	Pediatric liquids and suspensions	Dose uniformity and regulatory acceptability

Excipient selection should be based on the target product profile. A product seeking simple generic substitution should minimize novel excipient risk. A premium product can justify a more complex formulation if it produces a clinically meaningful improvement in exposure consistency or administration.

What FDA regulatory pathway applies to new itraconazole formulations?

A conventional generic capsule may use the ANDA pathway if it demonstrates pharmaceutical equivalence and bioequivalence to the applicable reference-listed drug. A product with a different formulation, dosage form, strength, or clinical use may require a 505(b)(2) application.

The likely regulatory pathways are:

Product concept	Likely U.S. pathway	Key evidence
Conventional 100 mg capsule	ANDA	Pharmaceutical equivalence and bioequivalence
Improved dispersion capsule with different formulation	ANDA or 505(b)(2), depending on reference and claims	Comparative PK, dissolution, formulation characterization
65 mg SUBA-type capsule	505(b)(2) or product-specific pathway	PK, safety, efficacy bridging, clinical labeling
Cyclodextrin oral solution	ANDA if reference-equivalent; otherwise 505(b)(2)	Dose proportionality, excipient safety, PK
Pediatric sprinkle formulation	505(b)(2) or ANDA	Bioequivalence, dose uniformity, administration studies
New injectable or long-acting system	505(b)(2) or full NDA	Clinical pharmacology, safety, sterility, device data

The FDA Inactive Ingredient Database is important when selecting excipients for an ANDA. Novel concentration, route, dosage form, or patient population can trigger additional safety justification even when an excipient is previously approved elsewhere (U.S. Food and Drug Administration, 2024a).

What is the Orange Book status of itraconazole products?

Itraconazole capsules, oral solution, and branded enhanced formulations are drug products rather than biologics. Biosimilar competition is therefore not relevant. The competitive risks are generic ANDA filings, 505(b)(2) reformulations, authorized generics, and branded alternatives.

The Orange Book determines the reference-listed drug, therapeutic-equivalence codes, patent listings, and regulatory exclusivity information for applicable products. Original Sporanox composition and formulation protection has largely matured, making conventional generic competition commercially established. Product-specific patents and regulatory protections for enhanced formulations must be reviewed separately in the current Orange Book and FDA patent information.

A patent review should distinguish among:

1. Active-ingredient patents, which are generally expired for itraconazole.
2. Conventional capsule and pellet patents, many of which are mature or expired.
3. Enhanced-dissolution formulation patents.
4. Process patents covering dispersion, granulation, coating, or drying.
5. Method-of-use patents covering specific fungal infections or prophylaxis.
6. Packaging, device, and administration patents.

When does itraconazole lose exclusivity?

Itraconazole has already lost basic small-molecule exclusivity in the United States. The relevant commercial question is not when itraconazole itself loses exclusivity, but whether a particular enhanced product remains protected.

Product category	Exclusivity position
Active ingredient	Mature and off-patent
Conventional 100 mg capsules	Generic competition established
Oral solution	Generic and regional competition subject to product-specific approvals
Enhanced 65 mg capsules	Product-specific formulation and regulatory protections may remain relevant
New pediatric, injectable, or long-acting product	Potential 505(b)(2), orphan, pediatric, or formulation-related protection

A Paragraph IV challenge would target an unexpired listed patent associated with a branded product. For conventional itraconazole, the commercial risk is primarily ordinary generic competition. For a newer enhanced formulation, the risk shifts to formulation patent validity, infringement, and the ability of a generic applicant to design around the protected composition.

Which patent claims are most defensible for an itraconazole formulation?

The strongest claims generally combine a defined formulation structure with measurable performance.

Composition claims

Useful claim elements include:

• Itraconazole-to-polymer ratio
• Specific polymer combinations
• Defined amorphous content
• Particle-size distribution
• Surfactant concentration
• Cyclodextrin-to-drug ratio
• Lipid and cosolvent ranges
• Capsule-fill or pellet architecture

Broad claims covering itraconazole with a generic solubilizer are vulnerable to prior-art challenges. Narrower claims tied to stability, supersaturation, or a specific manufacturing process may provide better enforceability.

Performance claims

Performance-based claims may cover:

• Dissolution at specified pH values
• Reduced precipitation after intestinal pH transition
• Exposure under fed and fasted conditions
• Reduced intersubject variability
• Bioavailability relative to a reference product
• Stability after accelerated storage

These claims can be commercially meaningful, but they require robust analytical methods and carefully controlled clinical or dissolution data.

Method-of-use claims

Potential method-of-use opportunities include:

• Fungal prophylaxis in immunocompromised patients
• Treatment of chronic pulmonary aspergillosis
• Use in patients receiving acid-suppressive therapy
• Pediatric administration
• Dose adjustment based on therapeutic drug monitoring

Method-of-use patents face narrower market protection because physicians and pharmacists may use generic itraconazole for the same disease. They are more valuable when linked to a distinct formulation or dosing regimen.

How strong is the itraconazole patent estate?

The overall itraconazole patent estate is mixed.

The basic active ingredient estate is weak because itraconazole is an old generic active ingredient. Conventional capsule technology also faces extensive prior art. The stronger patent positions are likely to be product-specific and concentrated in:

• Amorphous dispersion compositions
• Enhanced dissolution profiles
• Defined polymer systems
• Manufacturing processes
• Specialized pediatric or hospital dosage forms
• Long-acting delivery systems

Patent strength should be scored against design-around risk, not patent count alone.

Factor	Conventional itraconazole	Enhanced formulation
Active-ingredient protection	Low	Low
Prior-art density	High	High but more technically segmented
Formulation differentiation	Limited	Moderate to high
Bioequivalence complexity	Moderate	High
Design-around risk	High	Moderate
Regulatory differentiation	Low	Moderate to high
Commercial pricing power	Low	Higher if clinical value is demonstrated

What generic entry risks exist for itraconazole?

Conventional capsule entry

Generic entry risk is high for conventional capsules because:

• The active ingredient is mature.
• The dosage form is established.
• Multiple manufacturers can use standard pellet or capsule manufacturing.
• Prescribers are familiar with substitution.
• Payers have incentives to prefer low-cost products.

Price erosion can be rapid when several ANDA holders enter. Manufacturing quality, supply reliability, and therapeutic drug monitoring support become important commercial differentiators.

Enhanced-formulation entry

Enhanced formulations face a different risk profile. A generic applicant may:

• Challenge listed patents under Paragraph IV
• Use a different polymer system
• Develop a non-infringing amorphous dispersion
• Seek approval under a different regulatory route
• Demonstrate bioequivalence with a distinct dissolution mechanism
• Compete through an authorized generic or licensing arrangement

The strongest defense is a combination of valid composition claims, process claims that are difficult to avoid, clinical differentiation, and supply-chain control over specialized excipients.

What commercial opportunities exist beyond generic capsules?

Pediatric itraconazole

Pediatric products remain attractive because capsule swallowing, dose flexibility, and taste are persistent limitations. A concentrated suspension, mini-tablet, sprinkle capsule, or taste-masked multiparticulate product could target:

• Infants and young children
• Pediatric oncology
• Hematopoietic stem-cell transplantation
• Chronic fungal infections requiring extended treatment

The product must establish dose uniformity across small volumes and support administration through feeding tubes where relevant.

Hospital and oncology formulations

A more predictable oral formulation could reduce variability in patients receiving multiple interacting drugs. Commercial positioning could focus on:

• Therapeutic drug monitoring support
• Standardized administration
• Reduced food and acid-suppression restrictions
• Hospital formulary use
• Patients unable to tolerate conventional capsules

Clinical claims must be supported by comparative pharmacokinetic and clinical data.

Long-acting delivery

Long-acting injectable or implantable itraconazole products could address adherence and prolonged prophylaxis. The technical barriers are substantial because itraconazole has low aqueous solubility and a complex pharmacokinetic profile. Candidate approaches include nanosuspensions, depot systems, and lipid carriers.

The opportunity is larger in patients with recurrent infection or prolonged immunosuppression, but development costs and safety requirements would be materially higher than for an oral reformulation.

Geographic expansion

Commercial opportunity is strongest in markets with:

• High generic substitution but limited advanced formulations
• Large transplant and oncology populations
• Limited access to therapeutic drug monitoring
• High use of acid-suppressive medicines
• Demand for pediatric antifungal products
• Fragmented access to branded enhanced formulations

A regional strategy may use a low-cost conventional generic in price-sensitive markets and a differentiated dispersion or liquid product in hospital and specialty markets.

How does itraconazole compare with competing triazole antifungals?

Drug	Formulation position	Main competitive strength	Main limitation
Itraconazole	Capsules, oral solution, enhanced capsule platforms	Broad experience, generic availability, multiple dosage forms	Variable absorption and interaction burden
Posaconazole	Delayed-release tablet, oral suspension, IV	Strong prophylaxis position and improved tablet exposure	Cost and drug interaction concerns
Voriconazole	Tablets, suspension, IV	Broad invasive fungal treatment use	Visual, hepatic, metabolic, and interaction liabilities
Isavuconazole	Capsules and IV	Predictable modern product platform and shorter QT effect	Higher branded cost and narrower access
Fluconazole	Tablets, suspension, IV	Low cost and predictable absorption	Narrower activity against molds

Itraconazole remains commercially relevant where cost, clinical familiarity, and activity against selected molds are important. Its principal weakness is inconsistent exposure. New excipient systems should target that weakness rather than compete only on capsule price.

What manufacturing and intellectual-property barriers affect itraconazole?

The manufacturing barriers are higher than the chemistry of itraconazole alone suggests.

Critical process capabilities include:

• Uniform drug layering onto sugar spheres
• Hot-melt extrusion or spray drying for amorphous dispersions
• Moisture-controlled storage
• Particle-size control
• Polymer-drug mixing at commercial scale
• Pellet coating without agglomeration
• Capsule-fill weight control
• Protection against recrystallization

Manufacturers also face supply risks for specialty polymers, cyclodextrins, lipid excipients, and coating materials. A formulation that depends on one qualified supplier may have a weaker commercial profile than a technically similar product using multiple compendial sources.

The most defensible manufacturing patents cover process parameters that determine the final solid state or dissolution profile. Process claims are less valuable when a competitor can reproduce the same product using a different manufacturing route.

What licensing opportunities exist for itraconazole excipient technology?

Potential licensing structures include:

• Polymer-based amorphous dispersion platforms
• Cyclodextrin solubilization systems
• Nanocrystal manufacturing technology
• Pediatric taste-masking platforms
• Softgel and self-emulsifying delivery systems
• Therapeutic drug monitoring and adherence programs
• Regional rights for enhanced itraconazole formulations

A license should be evaluated against four commercial variables: freedom to operate, regulatory bridging burden, manufacturing transferability, and the ability to maintain pricing after generic entry.

A formulation license has greater value when it includes validated scale-up data, stability results, bioequivalence methodology, and rights to process improvements. A patent-only license is weaker because itraconazole has dense prior art and substantial design-around potential.

Key Takeaways

• Itraconazole’s commercial value is driven by formulation performance, not active-ingredient exclusivity.
• Amorphous solid dispersions offer the strongest opportunity for a differentiated oral capsule.
• Cyclodextrin liquids remain relevant for pediatric, dysphagic, and hospital populations.
• Conventional capsules face high generic-entry risk and limited pricing power.
• Enhanced formulations may support 505(b)(2) strategies, formulation patents, and specialty pricing.
• Patent value is concentrated in composition, process, dissolution, stability, and administration claims.
• Biosimilar risk does not apply because itraconazole is a small-molecule drug.
• Pediatric, hospital, long-acting, and regional formulations offer the clearest expansion opportunities.
• Manufacturing control over pellet layering, solid-state stability, and specialty excipients is a material competitive barrier.
• A commercial strategy should prioritize predictable exposure, simpler administration, and clinically supported differentiation.

FAQs About Itraconazole Excipient and Commercial Strategy

Can itraconazole be formulated as a conventional tablet?

Yes, but a conventional tablet must address poor dissolution and pH-dependent absorption. A tablet without a solubilization or dispersion strategy may have weaker exposure performance than pellet, lipid, or amorphous-dispersion systems.

Which excipient is most important for improving itraconazole bioavailability?

No single excipient is universally optimal. Hypromellose acetate succinate is highly relevant to amorphous solid dispersions, while hydroxypropyl-beta-cyclodextrin is central to liquid solubilization. The best choice depends on the target dosage form and regulatory pathway.

Is a 65 mg itraconazole capsule therapeutically equivalent to a 100 mg capsule?

Not automatically. Enhanced 65 mg products use a different formulation technology and dosing basis. Milligram-for-milligram substitution should not be assumed without product-specific labeling and pharmacokinetic evidence.

Could a new itraconazole formulation obtain orphan-drug exclusivity?

Potentially, but orphan designation depends on the indication, disease prevalence, clinical rationale, and statutory criteria. A new excipient system alone does not create orphan exclusivity.

What is the most attractive first product for an itraconazole developer?

A differentiated oral solid dispersion capsule is generally the most commercially practical first product. It has a lower development burden than an injectable or long-acting system and can target the principal weakness of conventional itraconazole: variable exposure.

References

1. Janssen Pharmaceuticals, Inc. (2023). Sporanox (itraconazole) capsules and oral solution prescribing information. U.S. Food and Drug Administration.

2. Mayne Pharma International Pty Ltd. (2018). Tolsura (itraconazole) capsules prescribing information. U.S. Food and Drug Administration.

3. U.S. Food and Drug Administration. (2018). Tolsura approval letter and multidisciplinary review. Center for Drug Evaluation and Research.

4. U.S. Food and Drug Administration. (2024a). Inactive ingredient database. Center for Drug Evaluation and Research.

5. U.S. Food and Drug Administration. (2024b). Approved drug products with therapeutic equivalence evaluations: Orange Book. Center for Drug Evaluation and Research.

6. U.S. Food and Drug Administration. (2017). Itraconazole clinical pharmacology and biopharmaceutics review. Center for Drug Evaluation and Research.

7. European Medicines Agency. (2023). Sporanox product information. Amsterdam: European Medicines Agency.

8. Ashraf, N., & Najib, N. M. (2013). The pharmacokinetics of itraconazole in humans and its formulation challenges. Clinical Pharmacokinetics, 52(5), 343-356.

9. Barone, J. A., Mosley, C. A., & Garris, R. E. (1998). Enhanced bioavailability of itraconazole using a cyclodextrin formulation. Pharmacotherapy, 18(2), 333-341.